Loading company…
OrangeBiomed develops a portable microfluidic device for diagnosing and monitoring diabetes.
Founded in 2021, OrangeBiomed develops diabetes testing and monitoring devices using microfluidic technology. Its OBM rapid A1c point-of-care device measures glycated hemoglobin and returns results in five minutes, for use in clinics or at home. Based in Seoul, South Korea, the company raised KRW 1 billion in venture funding from Intops Investment in January 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in